Clinical data
ATC code
  • none
Legal status
Legal status
  • In general: unscheduled
  • 2-methyl-1-phenylbut-3-yne-1,2-diol
CAS Number
PubChem CID
CompTox Dashboard (EPA)
Chemical and physical data
Molar mass176.215 g·mol−1
3D model (JSmol)
  • OC(c1ccccc1)C(C#C)(O)C
  • InChI=1S/C11H12O2/c1-3-11(2,13)10(12)9-7-5-4-6-8-9/h1,4-8,10,12-13H,2H3 ☒N
 ☒NcheckY (what is this?)  (verify)

Centalun was developed by Boehringer Ingelheim in 1962[1] and is a psycholeptic drug with hypnotic and sedative effects, via allosteric agonism of the GABAA receptor.[2] It was previously used for sedation in medical procedures such as surgery,[3] orthopedics[4] and gynecology,[5] although it is no longer in clinical use. Despite its history of clinical use, centalun was never incorporated into the CSA and therefore remains unregulated as a drug of abuse.


  1. ^ BE 618130, "Procédé pour l'obtention d'alkinediols" 
  2. ^ Janke W, Glathe H (June 1964). "[Experimental Studies on the Psychic Effect of Sedatives Under Normal and Stress Conditions]". Psychologische Forschung (in German). 27: 377–402. doi:10.1007/bf00421338. PMID 14233519. S2CID 144088161.
  3. ^ Monecke K (July 1964). "[Pre- and Postoperative Use of Centalun in Surgery]". Deutsches Medizinisches Journal (in German). 15: 470–1. PMID 14238754.
  4. ^ Bruckschen E (July 1964). "[Sedative Therapy with Centalun in Orthopedics]". Deutsches Medizinisches Journal (in German). 15: 493–4. PMID 14243120.
  5. ^ Gerlach W, Gerlach E (March 1964). "[Experiences with Centalun in Obstetrical and Gynecological Patients]". Medizinische Monatsschrift (in German). 18: 131–3. PMID 14193290.